Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

BioIndustry Association

- PMLiVE

Ipsen announces launch of new UK headquarters in London life sciences community

The Paddington site will serve as one of the company’s three global hubs

- PMLiVE

ABPI publishes manifesto for government to accelerate UK life sciences industry

The trade association has called on political parties to commit to three broad goals and requirements

- PMLiVE

UK’s Autumn Budget details measures to boost life sciences sector

The new budget will aim to advance research and manufacturing in the UK

- PMLiVE

ABPI report shows improvement in UK industry clinical trial performance

The data showed a 15% increase in annual recruitment to UK industry clinical trials

- PMLiVE

BioIndustry Association reveals how UK is set to become a global leader in mRNA

Several companies and organisations have supported the development of mRNA

- PMLiVE

mRNA technology for universal flu vaccine shows early promise in US study

The evolving nature of influenza viruses requires frequent reformulation of vaccines

- PMLiVE

Pfizer doses first patients with mRNA-based influenza vaccine

Available vaccine strains that match circulating influenza viruses offer only 40%-60% protection

- PMLiVE

Sanofi to buy acne specialist Origimm

The acquisition brings Origimm’s ORI-001 vaccine candidate against acne vulgaris into Sanofi’s vaccine pipeline, building its strength in mRNA technology

dengue fever mosquito

BioNTech to use mRNA technology to develop a ‘highly effective’ malaria vaccine

The company aims to develop a vaccine candidate and also boost mRNA manufacturing capabilities on the African continent

- PMLiVE

BioNTech plans acquisition of Kite’s TCR cell therapy R&D platform

German biotech company said the acquisition will boost its presence in the US

- PMLiVE

Moderna launches phase 1/2 study of mRNA-based flu vaccine

Vaccine will target flu lineages currently recommended by the World Health Organization

Sanofi reception

Sanofi to invest €400m annually in mRNA vaccines facility

French pharma company will build end-to-end R&D of ‘next-generation’ mRNA vaccines

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links